ReviewFrontiers in aging neuroscience2026
Sex hormones in the nucleus incertus: a novel perspective on sex/gender differences in memory and mood dysfunction in Alzheimer's disease.
Review in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
About 60% of the individuals living with Alzheimer's disease (AD) in the United States are women. Increasing evidence points to a role for sex hormones, especially estrogen, in making women more vulnerable to AD than men. Several brainstem signaling pathways, as well as multiple neuropeptide modulators and their receptors, are implicated in AD pathology and therapeutic possibilities. However, there is limited research evaluating how the modulatory effects of sex hormones on mood and cognition interact with these brainstem systems. This review seeks to examine possible connections between the nucleus incertus (NI) relaxin-3/relaxin-family peptide receptor 3 (RLN3/RXFP3) system and sex hormone influences in AD to encourage further investigation into how sex hormones may modulate this pathway and contribute to sex differences in disease risk and progression. Understanding how hormone-based interventions, such as hormone replacement therapy (HRT) and hormonal contraceptives (HC), affect NI RLN3/RXFP3 signaling may provide novel insights into how these treatments can slow AD-associated cognitive decline. It is hoped that this data and concept synthesis will drive detailed investigations of these circuits and support the development of sex/gender-informed therapeutic strategies that better reflect the heterogeneity of AD dementia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.